Eyes absent homolog 2 Antibodies

Eyes absent homolog 2 (EYA2)

Functions both as protein phosphatase and as transcriptional coactivator for SIX1, and likely also for SIX2, SIX4 and SIX5 (PubMed:12500905, PubMed:23435380). Tyrosine phosphatase that dephosphorylates'Tyr-142' of histone H2AX (H2AXY142ph) and promotes efficient DNA repair via the recruitment of DNA repair complexes containing MDC1.

'Tyr-142' phosphorylation of histone H2AX plays a central role in DNA repair and acts as a mark that distinguishes between apoptotic and repair responses to genotoxic stress (PubMed:19351884). Its function as histone phosphatase may contribute to its function in transcription regulation during organogenesis.

Gene Information

Human
Gene Name:	EYA2
Uniprot:	O00167
Entrez:	2139

Family

Belongs to:
HAD-like hydrolase superfamily

Alternative Names

EAB1EC 3.1.3.48; eyes absent (Drosophila) homolog 2; eyes absent homolog 2 (Drosophila); eyes absent homolog 2; MGC10614

Molecular Weight

Mass (kDA):
59.232 kDA

Genomic Context

Human
Location:	20q13.12
Sequence:	20; NC_000020.11 (46894624..47188844)

Tissue Specificity

Highest expression in muscle with lower levels in kidney, placenta, pancreas, brain and heart.

Subcellular Localizations

Cytoplasm. Nucleus. Retained in the cytoplasm via interaction with GNAZ and GNAI2 (PubMed:10906137). Interaction with SIX1, SIX2, SIX4 or SIX5 is required for translocation to the nucleus (PubMed:10906137, PubMed:12500905).

Diseases

• Malignant Neoplasms
• Neoplasms
• Neoplasm Metastasis
• Carcinoma
• Crest Syndrome
• Branchio-oto-renal Syndrome
• Malignant Neoplasm Of Breast
• Adenocarcinoma
• Hypertrophy
• Cardiac Hypertrophy
• Sarcoma
• Fibrosis
• Scleral Diseases

• Peripheral Nerve Sheath Neoplasm
• Nerve Sheath Tumors
• Non-small Cell Lung Carcinoma
• Malignant Paraganglionic Neoplasm
• Malignant Peripheral Nerve Sheath Tumor
• Inflammation
• Congenital Ocular Coloboma (disorder)

Interacting Proteins

• SIX1

Pathways

• Eye Development
• Cell Death
• Neurogenesis
• Somitogenesis
• Localization
• Limb Development
• Cell Differentiation
• Cell Proliferation
• Methylation
• Pathogenesis
• Rna Interference
• Cell Adhesion
• Cell Activation

• Programmed Cell Death
• Gene Silencing
• Olfactory Placode Development
• Olfactory Placode Formation
• Tube Formation
• Cell Fate Determination
• Tendon Development

PTMs

• Phosphorylation

• Methylation

• Dephosphorylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/EYA2

Boster Bio: Best Uses Of The EYA2 Marker Antibody

Primary antibodies are valuable for your research. Steven Boster's antibodies have high affinity, are highly cited and validated for use in Western Blotting, Immunohistochemistry, and ELISA. They can be trusted. This article will provide additional information on Boster’s primary antibodies and their use in research. Read on to learn more.

Boster Bio: Primary antibodies

Steven Boster, who invented his first product in 1993, earned the nickname "he that converts science into the lavatory". He quickly developed hundreds of primary antibodies, and his company became one of the largest catalog antibody companies in China. PicoKine(tm), which he developed himself, was his proprietary ELISA platform. This technology uses proprietary trade secrets in order to deliver high-sensitivity ELISA Kits.

Cells were harvested, and protein extracts were prepared with lysis buffer. Equal amounts of protein was electrophoresed in 10% SDS/PAGE gels. Finally, the membranes were transferred to PVDF membranes. After incubating the membranes for 30 minutes with diluted primary antibodies, they were visualized using AlphaView software on a FluorChemQ machine. After incubation, the membranes were exposed to horseradish peroxidase-conjugated secondary antibodies. Image J was used to analyze the intensity of the bands.

Dual-labeled specimens are possible with the primary antibody/secondary antibody system. This allows researchers to ask more questions, and to get more context data. Combining these technologies allows researchers to obtain more answers and more data with fewer resources. There are many benefits to this new technology. First, you'll find that it's easier to perform more complex experiments. You can identify cancer by using the EYA2 marker and other antibodies.

Primary antibodies used by Steven Boster

Boster Bio supplies high-sensitivity, high specificity ELISA kits for life scientists and compatible WB/IHC antibodies since 1993. These products have been thoroughly tested and approved for use in multiple applications. Boster's quality assurance guarantee protects customers' investment. Their extensive product ranges and ongoing research and development ensure that they provide the best quality products for your work.

Primary antibodies are immunoglobulins that recognize a biomolecule and bind it. They are made by immunizing host animals with specific antigens and extracting the antibodies from their sera or eggs. Although the process of creating primary antibodies is very similar to that of secondary antibodies, it is often easier. Primary antibodies have the advantage of being able to detect, purify and measure the antigen of your interest.

Primary antibodies are of great value

The EYA2 genome encodes transcription cofactors that are essential for eye development. They play an important part in organ development and multiple signaling paths. Recent studies have shown Eya2 may play an important role for cancer metastasis, proliferation, and progression. Eya2 overexpression is associated with poorer patient survival. Eya2 deficiency also affects viability and growth of HPV-16 transformed cervical carcinoma keratinocytes.

EYA2 expression was highest in PML–RARA AML (PML–RARA APL), while it is low for other subtypes. It is possible the induction EYA2 expression by PML-RARA in vitro immortalization of mouse progenitor cells could be related to the development and atypical PML -RARA APL.

EYA2 gene expression is high in breast cancer and many other types of cancer. It is possible to stop the progression of cancer by targeting this gene. Six1 function can be impaired and side effects are limited. EYA2 and SIX1 do not have high levels in adult tissues. However the EYA2-mediated interaction could be a therapeutic target. This target could stop tumor progression and cause very few side effects if it succeeds.

In addition to cancer cells, EYA2 is also expressed in astrocytoma. Its expression correlated with tumor grade. Eya2 is a tumor-fighting agent. Six1 regulates ERK Signaling. In addition, Eya2 serves as an oncoprotein in human astrocytoma. EYA2 is also important for the development gliomas.

Quantitative studies with primary antibodies require that the secondary antibody cross-reacts with the target protein. It is possible to use fluorophore-conjugated primary antibodies for this purpose. This allows for quantitative experiments to be simplified without the need of secondary antibodies. You can also use noncommercial direct conjugates as an alternative for fluorescent-labeled Secondary Antibodies.

EYA2 has been recognized as a useful marker when it comes to screening breast-cancer samples. This study also revealed that EYA2 expression was increased in breast cancer cells when miR-338-3p was inhibited. This shows that a primary antibody against EYA2 can be extremely specific for breast carcinoma cells. It is not yet clear if secondary antibodies will cross-react to breast cancer tissues.

Eya2 plays a role in the development of the eye. It also has many biological functions, such as the upregulation MMP9 by PLZF–RARA. This gene is also involved with the aberrant self-renewal process in neurons. This makes the primary antibody for EYA2 a useful tool to detect these protein. It can also be used in research by being found in the EYA2 gene repository.